| 3 | Utility of convalescent plasma for addressing the COVID-19 infection: brief review and case reports显示文摘Novel coronavirus,SARS-CoV-2 is responsible for causing a pandemic that has affected individuals worldwide,over 192 million people and about 4.1 million people died so far.The spread is ongoing and the numbers are still increasing.Numerous therapeutic approaches have been explored and developed during this pandemic.Immunotherapy with virus-specific antibodies in convalescent plasma(CP)has shown potential benefits for various pathogenic diseases.In many instances,it is the only available and safe management option for the COVID-19 patients.Here we describe two confirmed cases of COVID-19 from two different geographical areas that were managed with standard treatment modalities initially.Both of the patients were presented with high-grade fever,dry cough,and sore throat.Lab reports showed increased values of D-dimer,serum ferritin,leukocyte count(LC),Lactate dehydrogenase(LDH),and C-reactive protein(CRP).Chest X-ray showed bilateral infiltration(multifocal and bilateral ground-glass opacities and consolidations with peripheral and basal predominance),consistent with the previous reports on COVID-19 infection.The patients received conservative treatment according to the hospital's protocol.The convalescent plasma(from recovered patients)infusion was the last treatment given to both patients.After the convalescent plasma transfusion,both patients showed a reduction of viral load,an increase of anti-SARS-CoV-2 IgG and IgM antibodies,reduction in lung infiltration,with no adverse events.However,further randomized controlled trials are needed to investigate the full scope of safety and efficacy(both short and long-term)of convalescent plasma therapy for COVID-19 and other related infections. | Fazli Azim Md Shahidul Islam Ashraful Hoque Muhammad Javed Aneela Hayat Kaniz Fatema Molla Amiruzzaman Md.Nasir Uddin Kajal Kumar Karmakar Syed A.A.Rizvi | 2022 | Life Research2022，5，1： | 0 |
| 4 | Vaccine efficacy and SARS-CoV-2 control in California and U.S.during the session 2020e2026:A modeling study显示文摘Background:Besides maintaining health precautions,vaccination has been the only prevention from SARS-CoV-2,though no clinically proved 100%effective vaccine has been developed till date.At this stage,to withhold the debris of this pandemic-experts need to know the impact of the vaccine efficacy rates,the threshold level of vaccine effectiveness and how long this pandemic may extent with vaccines that have different efficacy rates.In this article,a mathematical model study has been done on the importance of vaccination and vaccine efficiency rate during an ongoing pandemic.Methods:We simulated a five compartment mathematical model to analyze the pandemic scenario in both California,and whole U.S.We considered four vaccines,Pfizer(95%),Moderna(94%),AstraZeneca(79%),and Johnson&Johnson(72%),which are being used rigorously to control the SARS-CoV-2 pandemic,in addition with two special cases:a vaccine with 100%efficacy rate and no vaccine under use.SARS-CoV-2 related data of California,and U.S.were used in this study.Findings:Both the infection and death rates are very high in California.Our model suggests that the pandemic situation in California will be under control in the last quartile of the year 2023 if vaccination program is continued with the Pfizer vaccine.During this time,six waves may happen from the beginning of the immunization where the case fatality and recovery rates will be 1.697%and 98.30%,respectively.However,according to the considered model,this period might be extended to the mid of 2024 when vaccines with lower efficacy rates are used.On the other hand,the daily cases and deaths in the U.S.will be under control at the end of 2026 with multiple waves.Although the number of susceptible people will fall down to none in the beginning of 2027,there is less chance to stop the vaccination program if vaccinated with a vaccine other than a 100%effective vaccine or Pfizer,and at that case vaccination program must run till the mid of 2028.According to this study,the unconfirmed-infectious and infected cases will be under control at the end of 2027 and at the mid of 2028,respectively.Interpretation:The more effective a vaccine is,the less people suffer from this malign infection.Vaccines which are less than 90%effective do not have notable contribution to control the pandemic besides hard immunity.Furthermore,specific groups of people are getting prioritized initially,mass vaccination and quick responses are required to control the spread of this disease. | Md Shahriar Mahmud Md Kamrujjaman Md Mashih Ibn Yasin Adan Md Alamgir Hossain Md Mizanur Rahman Md Shahidul Islam Muhammad Mohebujjaman Md Mamun Molla | 2022 | Infectious Disease Modelling2022，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员